Jan. 23, 2018

Over the past couple of weeks in our main newsletter, Steve has introduced you to the idea of using software that includes considerations for insurance coverage and cost to pinpoint diabetes care. However, we all know that patients with diabetes have multiple disease states and we need to maximize therapy for all of a patient’s conditions. This week, in Part 4 of Steve’s interview with Dr. Ray Kausik, they look at the cardio benefit of using an SGLT-2 inhibitor with a PCSK9 inhibitor.

Dave Joffe

Editor-in-chief